Despite aggressive treatments the prognosis of high-grade gliomas remains poor. Meningiomas are generally benign but for high-grade histotypes or partially resected tumours, recurrence is fairly common. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival of brain tumour and meningiomas patients. Radioimmunotherapy (RIT) and peptide receptor radionuclide therapy (PRRT) represents two examples of targeted radiotherapy which offer exciting prospect of increasing the specificity of tumour cell irradiation using radionuclides. Although these treatments have been principally experimented for systemic approach, RIT and PRRT may also be exploited topically, in order to reduce systemic activity and enhance tumour targeting. In this chapter the authors report on intracavitary use of radionuclides in HGG and their experience concerning peptide receptor radionuclide therapy in meningiomas.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The authors wish to thank Mrs Deborah Console for editing the manuscript.
Bartolomei M, Mazzetta C, Handkiewicz-Junak D et al (2004) Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 48:220–228PubMedGoogle Scholar
Bartolomei M, Bodei L, De Cicco C et al (2009) Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407–1416PubMedCrossRefGoogle Scholar
Boiardi A, Bartolomei M, Silvani A et al (2005) Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 72:125–131PubMedCrossRefGoogle Scholar
Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–211PubMedCentralPubMedCrossRefGoogle Scholar
Liu BL, Cheng JX, Zhang X et al (2010) Controversies concerning the application of barchitherapy in central nervous system tumours. J Cancer Res Clin Oncol 136:173–185PubMedGoogle Scholar
Paganelli G, Grana C, Chinol M et al (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–353PubMedCrossRefGoogle Scholar
Paganelli G, Bartolomei M, Ferrari M et al (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–236PubMedCrossRefGoogle Scholar
Paganelli G, Bartolomei M, Grana C et al (2006) Radioimmunotherapy of brain tumor. Neurol Res. 28:518–522Google Scholar
Reardon DA, Rich JN, Friedman HS et al (2006) Recent advances in the treatment of malignant astrcytoma. J Clin Oncol 24:1253–1265Google Scholar
Schumacher T, Hofer S, Eichhorn K et al (2002) Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 29:486–493PubMedCrossRefGoogle Scholar
Stupp R, Mason WP, Van Den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozoloide for glioblastoma. New Eng J Med 352:987–996PubMedCrossRefGoogle Scholar
Zalutsky MR (2005) Current status of therapy of solid tumors: brain tumour therapy. J Nucl Med 46: 151S–156SGoogle Scholar
Zalutsky MR, Reardon DA, Akabani G et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30–38PubMedCentralPubMedCrossRefGoogle Scholar
Zoller F, Eisenhut M, Haberkorn U et al (2009) Endoradiotherapy in cancer treatment—basic concepts and future trends. Eur J Pharmacol 625:55–62Google Scholar